Related Experiment Video
Updated: Jun 30, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Specialist Inpatient Detoxification from Gabapentinoids: Clinical and Demographic Characteristics and Predictors of
Aansha Priyam1, Andrew Hill1, Mostafa Abdellatif1
1Greater Manchester Mental Health NHS Foundation Trust, Addictions Services, Manchester, UK.
Abstract:
Gabapentinoids are increasingly implicated in drug-related deaths, and little is known about the harms of dependence or detoxification outcomes. Abrupt cessation is associated with adverse events, such as seizures, yet no standardized withdrawal scales or treatment regimens exist. This study describes the clinical and demographic characteristics of people undergoing specialist inpatient gabapentinoid detoxification in a large, regional unit in Manchester, United Kingdom, and explores predictors of treatment outcome. The sample included all patients (n = 38) admitted for gabapentinoid detoxification between years 2017-2022. Clinical data were analyzed using a retrospective observational cohort design to explore associations between baseline characteristics and outcomes. We hypothesized that people undergoing multiple detoxifications and/or detoxification for illicit gabapentinoid use would be more likely to have negative outcomes. This is the largest cohort undergoing inpatient detoxification from gabapentinoids studied till date. The majority were male, White British, unemployed, straight, with a mean age of 38.9 (SD = 8.9), and required detoxification from multiple substances (n = 35). The majority completed detoxification successfully. Relapse (p < .001), complications (p = .001), personality disorders (p = .034), a concurrent benzodiazepine (p = .011) or opioid detoxification (p = .025) were significantly associated with an incomplete detoxification. Illicit use of pregabalin, and multiple concurrent detoxifications were not related to outcomes. Further research is needed to optimize treatment.
Related Concept Videos
CNS Depressants: Barbiturates and Benzodiazepines
CNS Depressants: Alcohol and Nicotine
Drug Abuse and Addiction: Pharmacological Phenomena
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Toxicity: Risk factors
Drug Dependence
